# Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

> **NCT01613417** · PHASE4 · COMPLETED · sponsor: **Bracco Diagnostics, Inc** · enrollment: 229 (actual)

## Conditions studied

- Brain Disease

## Interventions

- **DRUG:** gadoteridol
- **DRUG:** gadobutrol

## Key facts

- **NCT ID:** NCT01613417
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613417, "Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01613417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*